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TCL1 transgenic mouse model as a tool for the study of
therapeutic targets and microenvironment in human
B-cell chronic lymphocytic leukemia
A Bresin1, L D’Abundo2, MG Narducci1, MT Fiorenza3, CM Croce4, M Negrini*,2 and G Russo*,1
Chronic lymphocytic leukemia (CLL) is a B-cell malignancy with a mature phenotype. In spite of its relatively indolent nature, no
radical cure is as yet available. CLL is not associated with either a unique cytogenetic or a molecular defect, which might have been
a potential therapeutic target. Instead, several factors are involved in disease development, such as environmental signals which
interact with genetic abnormalities to promote survival, proliferation and an immune surveillance escape. Among these, PI3-Kinase
signal pathway alterations are nowadays considered to be clearly important. The TCL1 gene, an AKT co-activator, is the cause of a
mature T-cell leukemia, as well as being highly expressed in all B-CLL. A TCL1 transgenic mouse which reproduces leukemia with a
distinct immunophenotype and similar to the course of the human B-CLL was developed several years ago and is widely used by
many groups. This is a review of the CLL biology arising from work of many independent investigators who have used TCL1
transgenic mouse model focusing on pathogenetic, microenviroment and therapeutic targets.
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Facts
 Aggressive form chronic lymphocytic leukemia (CLL) is still
incurable.
 The TCL1-tg mouse model is most similar to aggressive
human CLL.
 The TCL1-tg model has fundamentally contributed to the
elucidation of CLL pathogenic mechanisms.
 Many novel therapeutic strategies have been tested using
TCL1-tg mice.
Open Questions
 Can new combination therapies be investigated using the
TCL1-tg model?
 Can microenvironment contribution and tumor immune
suppression be more easily studied through animal models
than in human patients?
 Can microRNAs targeting TCL1 or TCL1-specific inhibitors
be used as therapies against CLL?
CLL is the most common B-cell malignancy in Western
countries. CLL lymphocytes are similar to memory B-cells
bearing a mature immunophenotype and showing different
activation and maturation states.1 CLL patients manifest
distinct disease courses2,3 and prognostic molecular markers
identify patients at different risk: leukemic clones with few
IgHV-genemutations (U-CLL) but withmanyCD38+or ZAP70+
B-cells, lead to an aggressive disease, chemotherapy
resistance and is usually fatal; clones with mutated IgHV
(M-CLL), few CD38+ or ZAP70+ B-cells, exhibit an indolent
asymptomatic course which generally responds to therapy.4
The monoclonal nature of leukemic cells suggests the
existence of genetic lesions in the CLL. Recurrent cytogenetic
aberrations include: deletion at 13q14.3 (55% of cases) is
associated with an indolent form and loss of miR-15a and
miR-16-1 genes;5 deletions at 17p13 (7%) or 11q22-23 (18%)
with consequent loss of TP53 at 17p, ATM and miR-34b/
miR-34c at 11q are associated with amore aggressive form;6,7
trisomy 12 (16%) is associated with an intermediate form of
CLL. Nucleotide sequencing has discovered recurrent muta-
tions in a number of genes such as TP53, NOTCH1, SF3B1,
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BIRC3 and ATM, which are indicative of derailed multiple
pathways in CLL cells. It is also known that p53 mutations
result in selective resistance to alkylating agents, such as
fludarabine. In addition, treatment with DNA-damaging agents
is correlated with an occurrence of p53 mutations in a clinical
setting.8 Besides genetic lesions, pathogenic mechanisms
may also represent survival signals arising from the micro-
environment, through the B-cell receptor (BCR), integrins,
chemokines and cytokine receptors, which allow CLL cells to
actively proliferate and accumulate.9,10
In addition, the T-cell leukemia-1 oncogene (TCL1) is
expressed in almost all CLL patients and high-TCL1 protein
levels correlate with the aggressive prognostic markers such
as unmutated VH status, ZAP70 expression and chromosome
11q22-23 deletions.11 Accordingly, lower TCL1 levels are
associated with a higher probability of positive response to
chemoimmunotherapy.12 Animal models help to decipher
pathogenic mechanisms of a disease and to evaluate the
efficacy and mechanisms of novel therapies. A number of CLL
mouse models have recently been reviewed by Simonetti
et al.13 The authors compared different models and identified
the Eμ-TCL1 transgenic mouse (TCL1-tg) as the most similar
to aggressive type human CLL, in terms of immunophenotype,
BCR repertoire and disease course. Importantly, TCL1 over-
expression exhibits a 100% disease penetrance.
TCL1: Functions, Roles in CLL and Animal Models
The TCL1 gene was discovered as the causative oncogene of
T-prolymphocytic leukemia (T-PLL), where it is overexpressed
in almost 100% of cases by a chromosomal translocation.14
TCL1 is also expressed in human seminomas,15 and in CD4
+/CD56+ skin blastic tumors16 and in other B-cell lymphomas.17
TCL1 is a low-molecular weight protein and its first recognized
function was the activation of phosphoinositide 3-kinase (PI3K)
pathway, implicated in cell proliferation and survival (Figure 1),
through direct bindingwith the AKT1/2 kinases.18 TCL1binds to
several other proteins and among these interacting proteins,
the most relevant in CLL are: the receptor tyrosine kinase-like
orphan receptor-1 (ROR1),19 the p300 transcription factor and
the AP1 components FOS and JUN,20 the NFkB inhibitor
alpha (IkBα),21 the XBP1 transcription factor22 and the DNA
methyltransferases (DNMTs)23,24 (Figure 2).
Physiologic functions of TCL1 protein mainly concern B-cell
maturation, early embryonic development and stem cells
regulation.15,17,25–27 Physiological roles of TCL1 was eluci-
dated also by modifying TCL1 expression in mice. The
knocking out (KO) of Tcl1 shows light impairment in B- and
T-cell differentiation,28 while KO has stronger phenotypes in
the embryonic stem cell proliferation/differentiation balance,29
embryo development15 and skin, especially in the hair follicle
regeneration.27 This last KO phenotype is rescued when the
strain is crossed to a TCL1 transgenic mouse specific for
epidermal basal layer, under the Keratin14-promoter.27
The overexpression of TCL1 in transgenic animal
models recapitulates faithfully leukemia of T-cell or B-cell
origin according to the promoter used: the overexpression of
TCL1 in T cells under Lck-promoter, recapitulates human
T-PLL30 and the overexpression of TCL1 in B cells under
the VH-promoter-IgH-Eμ-enhancer (TCL1-tg), recapitulates
CLL.31,32 As in humans, leukemia developed in the TCL1-tg
model is characterized by clonal expansion of B cells with
B220+/IgM+/CD5+ immunophenotype, unmutated IGHV,
increased proliferation and enhanced AKT phosphorylation,
which represent an aggressive form of CLL.31–33 Leukemic
cells are firstly detected in the peritoneal cavity, at 2 months
age; then tumor cells become detectable in peripheral blood
(PB) and expand to the spleen (at 4 months) and bonemarrow
(BM; at 8 months).31 Tumor cells in TCL1 mice have wild-type
(WT) p53 and initially respond to fludarabine treatment, after
which drug resistance develops.34 Notably, the leukemic cells
from a TCL1-tg donor can be transplanted by intra-peritoneum
or intra-venous injection into syngeneic WT or immunodefi-
cient mice (e.g., SCID) to accelerate the disease course and to
generate a genetically homogeneous population of leukemic
mice, which allows for the systematic study of novel therapies,
without waiting for its natural course in non-transplanted
animals. This technique can further be emphasized by serially
adoptive cell transfer of leukemic cells into SCID mice. The
repeated transplantations result in a clonal selection of B cells,
which can be used for the analysis of particular conditions, for
instance, BCR specificity.
Therapeutic Targets in TCL1-tg Mouse Models
Nowadays, many studies have used these TCL1-tg mouse
models (Table 1), and then contribute to our present knowl-
edge of CLL biology and generate fundamental data for the
development of new therapeutic approaches aimed at the
overcome of drug resistance and the curative treatment of
CLL. The following is a review of the data obtained from these
mice models.
PI3K/AKT pathway. As mentioned above, TCL1 directly
binds to AKT (Figure 1) which enhances its phosphorylation
and nuclear translocation.18,35 AKT, originally isolated from
leukemia and lymphoma-prone mice cells, is over expressed
in many tumors and is a key factor in CLL, integrating survival
and proliferative signals from the environment through BCR,
growth factors, integrins, chemokines and TNF receptors.36
Oral administration of the AKT-inhibitor OSU-T315 in mice
transplanted with TCL1-tg cells was shown to prolong
survival37 and allowed for the elucidation of the drug mech-
anism acitivity: OSU-T315 displaces AKT from lipid rafts, thus
impairing AKT activation regardless of activating pathways.
One of the AKT downstream factors is the protein kinase
mammalian target of rapamycin (mTOR), which controls cell
growth, proliferation and survival. Zanesi et al. established a
syngenic transplantation model, where leukemic cells isolated
from a TCL1-tg donor spleen can be indefinitely maintained
in vivo. Treatment of transplantedmicewith themTOR inhibitor
rapamycin slowed leukemia and prolonged survival.38
Recently, exciting results have been published using the
dual PI3K/mTOR inhibitor PF-04691502 on the TCL1-tg.39
PF-04691502 is a potent antitumor agent able to inhibit all the
PI3K isoforms and both the mTOR complexes 1 and 2
(mTORC1/2). This is necessary to overcome redundancy
between PI3K isoforms and mTORC2 positive feedback on
AKT phosphorylation, which were observed with the Food and
Drug Administration (FDA)-approved specific inhibitors of
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PI3Kδ (idelalisib) and mTORC1 (everolimus). The study
revealed the pro-apoptotic activity of PF-04691502 through
caspase activation in both human and mouse CLL cells.
Moreover, in vivo treatment of TCL1-tg mice allowed for further
insight into the clinical effects of PF-04691502: inhibition of
CXCL12-mediated migration toward spleen and lymph nodes
(LNs) induced redistribution of the tumor cells from lymphoid
organs to the blood, followed by a marked reduction of tumor
burden due to the cytotoxic activity of the drug. The splenic
architecture was maintained in treated mice, although tumor
cells were not completely eradicated, reflecting some resistant
subpopulation.
Alternatively, the AKT pathway can be affected through
inhibition of upstream signals. For example, the insulin-like
growth factor-1 receptor (IGF1R) is overexpressed in CLL and
mediates IGF1-induced activation of PI3K/AKT and mitogen-
activated protein kinase/extracellular signal-regulated kinase
(ERK) pathways. Inhibition of IGF1R by oral administration of
linsitinib in TCL1-tg mice produced a significant decrease in
malignant cells.40
Also, AKT phosphorylation can be enhanced through
overexpression of ROR1. TCL1/ROR1 double-tg mice
revealed the formation of complexes between the two factors
and more aggressive leukemia due to increased proliferation
and decreased apoptosis. In vivo administration of anti-ROR1
specific antibody, D10 revokes the potentiating effect of ROR1
on TCL1-tg cells, suggesting that this may be a novel
therapeutic target in ROR1-expressing cancers.19
Figure 1 Targeting of BCR and PI3K/AKT signaling as therapeutic strategy in CLL. BCR signaling has a major role in the development of CLL. After antigen ligation on BCR,
three main protein tyrosine kinases, LYN, SYK and BTK, are activated. PLC2 and PI3K are important downstream effectors of BCR signaling. PI3K activates downstream kinases
such as AKT, which in turn induces NFkB and mTOR routes. Activation of PLC2 leads to the release of intracellular Ca2+ and activation of PKC, both of which are crucial for the
activation of mitogen-activated protein kinases (MAPKs), such as ERK, c-JUN NH2-terminal kinase (JNK) and p38 MAPK and transcription factors, including NFκB. PI3K/AKT
pathway can be induced also by tyrosine kinase receptors such as IGFR1 and ROR1. TCL1 enhances AKT signal and can sustain activation of the BCR downstream factors SYK
and LYN by indirect inhibition of the phosphatase PTPROt. Red symbols and letters indicate new therapeutic targets as discussed in the text
Figure 2 TCL1 function in CLL pathogenesis. TCL1 binds and regulates
molecular factors implicated in proliferation, survival, inhibition of apoptosis and
epigenetic regulation, thus contributing to CLL transformation
TCL1 mouse model in CLL
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Finally, the overexpression of a member of the protein
kinase C family, PKCβ, involved in signal transduction of
growth factors and BCR and known to be a PI3K-independent
AKTactivator, correlates with poor-prognosis in CLL patients.
The cross talk between TCL1/AKT and PKCβ was demon-
strated in TCL1-tg mouse.41 In fact, genetic removal of PKCβ
prevents CLL development in crossed TCL1-tg/Pkcβ− /−mice.
However, TCL1 overexpression restores AKT signaling and
B-cells production, which were abrogated in parental Pkcβ− /−
mice, suggesting hierarchical order with TCL1/AKT acting
downstream to PKCβ. Besides the examination of the PKC/
TCL1/AKT route in CLL, these results led to the in vitro
evaluation of enzastaurin, which inhibits both PKCβ and AKT,
for therapeutic activity in CLL cells and subsequently to clinical
trials (NCT00452257; Figure 1).
Nuclear factor kappa-light-chain-enhancer of activated B
cells (NFkB). Anti-apoptotic activity of NFkB, mainly acti-
vated through BCR signaling, is an important factor in CLL
etiology and several pieces of evidence indicate that TCL1 is
involved in NFkB activation (Figure 2). TCL1 interacts with the
p300 transcription factor, enhancing its ability to activate
NFkB in human B cells.20 Also, TCL1 can directly interact
with ATM and the NFkB inhibitor IkBα, thus enhancing the
phosphorylation and degradation of IkBα, with consequent
activation of NFkB both in human and mouse CLL.21 In vivo
treatment with the inhibitor of chaperone protein HSP90
(17-DMAG or alvespimycin), depletes IkB kinase complex
subunits (IKK) and inhibits NFkB transcriptional activity,
resulting in reduced expression of anti-apoptotic proteins
BCL2 and MCL1 and caspase-dependent apoptosis.42 The
17-DMAG is being tested in phase I clinical trials in CLL
patients (NCT01126502).
Endoplasmic reticulum (ER) stress response. ER stress
response and IRE1/XBP1 pathway are aberrantly activated in
human CLL and in TCL1-tg mice.22 TCL1 is directly involved
in ER response by physical interaction with XBP1 and
alteration of its transcriptional activity, resulting in constitutive
activation of BCR signaling and influencing cross talk with
other factors such as IRF4, BLIMP1 and AID. The importance
of the IRE1/XBP1 pathway in leukemia maintenance is
demonstrated by the observation that in vivo treatments with
the specific inhibitor A-106 selectively induces apoptosis in
TCL1-tg leukemic cells.22
On the other hand, prolonged activation of ER stress
response by reactive oxygen species (ROS) may be exploited
to induce cell death in CLL cells.43 Auranofin is a gold-
containing drug, currently used in the rheumatoid arthritis
treatment, which induces ROS levels. Oral administration of
this FDA-approved compound to TCL1-tg mice markedly
reduced leukemia expansion.43 Auranofin is currently investi-
gated in phase II clinical trial for CLL therapy (NCT01419691).
Epigenetic regulation. DNA methylation and histone
modifications shape gene expression without changes in
DNA sequences. Abnormalities affecting these epigenetic
events are implicated in pathological conditions, including
cancer and leukemia.Ta
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DNA methyltransferases: Methylation at cytosine residues
of DNA is realized by DNMTs and causes repression of
transcription. TCL1 appears to be directly implicated in such
epigenetic regulation, although, diverse reports describe
opposite roles. Chen et al. found increased methylation
levels in human as well as mouse CLL cells23 and identified a
repressor complex, constituted by TCL1, p50 subunit of NFkB
and histone deacetylase 1 (HDAC1), which induces tran-
scriptional silencing before DNA methylation. For example,
transcriptional repression of the inhibitor of DNA-binding
protein-4 (ID4) in TCL1 mice results in acceleration of
leukemia development.44 Conversely, Palamarchuk et al.
described decreased methylation levels in TCL1-tg mice and
in CLL patients.24 The authors found a strong interaction
between TCL1 and de novo DNMT3A and 3B, with a drastic
inhibition of enzymatic activity, suggesting a leukemogenesis
mechanism involving inhibition of de novo methylation.
However, Chen et al. observed the lack of DNMT3A and 3B
in the genesis of the transformation of splenocytes from
TCL1-tg mice, but increasing protein levels at later stages.45
Discrepancies in these data may reflect the complex timing of
epigenetic changes with early event required for transforma-
tion and secondary events accumulating as a consequence
of leukemogenesis. The analysis of the methylation status
and transcriptional activation of these genes in Tcl1− /− mice
might provide additional clues on this issue.
Deacetylases: Deacetylases (DACs) are a family of
enzymes, subdivided into classes I and II, which remove
acetyl groups from a broad range of proteins. Histone
proteins are the most studied target of DACs, but transcription
factors, chaperones and signaling components are as much
as important. Owing to the regulatory effects on cell growth
and differentiation, inhibitors of DACs possess antitumor
activity and are currently used in diverse solid cancers
therapy. For example, HDAC inhibitors facilitate the formation
of an active death-inducing signaling complex, leading to the
rapid activation of caspase-8.46 Preclinical studies have also
demonstrated the pro-apoptotic efficacy for class I-specific
DACs inhibitors (romidepsin) in CLL cells and are currently in
clinical trials. A novel class I/II DACs inhibitor, AR-42
(OSU-HDAC42) has been tested in a transplanted model of
TCL1-tg mouse47 and demonstrated to be more potent than
vorinostat, a pan-DAC inhibitor approved for cutaneous T-cell
lymphoma therapy. AR-42 treatment in these mice resulted in
diminished tumor growth and prolonged survival and this
compound is now in phase I clinical trial (NCT01129193).
MicroRNAs. MicroRNAs (miRNAs) are highly conserved
small noncoding RNAs that function in post-transcriptional
regulation. As miRNAs exhibit a variety of crucial functions
related to cell growth, development and differentiation,
dysregulation of miRNAs has been associated with diseases,
including cancer. The first evidence for miRNAs involvement
in human cancer was indeed from a study on CLL: 13q14.3
deletion, frequently observed in the patients, was shown to
remove two microRNA genes, miR-15 and miR-16; their loss
causes deregulation of BCL2.5,48–50 Subsequent studies,
with the support of the TCL1-tg mouse model, disclosed an
involvement of p53-miR15/16-MCL1 axis in the regulation of
resistance.51 Loss of p53 in TCL1-tg/p53− /− crossed mice
causes a decrease of miR15/16 together with an upregulation
of MCL1 and the consequent development of a more severe
CLL. This association is fully consistent with the poor
prognosis observed in CLL patients with the 17p deletion.
Extensive miRNA expression profiling on CLL cells from
well-annotated cohorts of patients, identified miRNA signa-
tures associated with prognosis and progression in B-CLL or
with cytogenetic subgroups.52–54 Thus, inhibition of ‘onco-
miRs’ by anti-miRs or replacement of tumor suppressor
miRNAs by mature sequence oligos (mimics) may represent
novel therapeutic strategies. As CLL pathogenesis depends
on several pathways and a single miRNA may have hundreds
of mRNA targets, miRNA-based therapy might constitute a
multibranched approach with higher potentialities than spe-
cific inhibitors.55
We have recently explored the therapeutic potential of
miR-181b on the TCL1FL-tg mouse model.32 In addition, to its
known function tomodulate TCL1, MCL1 and BCL2,11,56,57 we
observed the ability of this miRNA to downregulate important
leukemia-promoting pathways such as AKT and ERK.58
Concordant with these findings, the treatment with miR-181b
mimics reduces leukemic expansion and prolongs overall
survival in TCL1FL-tg mice. This result represents the first
in vivo demonstration for therapeutic efficacy of miRNA
replacement strategy in CLL. Studies on additional miRNAs
as well as combination with other conventional or innovative
compounds might open new therapeutic possibilities, as
suggested by the overcoming of resistance to the BCL2
inhibitors, through down-modulation of MCL1 and PI3K/AKT/
mTOR pathway with siRNA or specific drugs.59
B-cell Receptor
CLL cells proliferate only in lymphoid organs, where accessory
cells (i.e., nurse-like cells (NLC), T cells and stromal cells)
provide the correct environment (mainly chemokines and
cytokines) to sustain proliferation and survival of malignant
cells9 (Figure 3). In this scenario, BCR signaling has a key role.
A large amount of data, either from patients’ studies or
experimental models, supports the hypothesis of sustained
antigen-dependent stimulation of BCR as a promoting event
for clonal amplification of CLL cells.1,10,60 The sustained
engagement of the BCR activates downstream targets such
as NFkB, AKTand ERK,61,62 which promote the expression of
anti-apoptotic proteins, mainly BCL2 and MCL1.36,63
BCR response is highly correlated with TCL1 levels in the
CLL cells and with the formation of activation complexes at
the BCR, by TCL1, AKT and ZAP70 kinases.64 Interplay
between TCL1 and BCR activity was also suggested by
studies on dnRag1/TCL1 double-tg.65 Enforced BCR auto-
reactivity, due to RAG1 impairment, induces an indolent
accumulation of CD5+ B cells, similar to monoclonal B-cell
lymphocytosis; the TCL1 overexpression provides an addi-
tional lesion on this background, promoting progression to
CLL. Moreover, TCL1 can sustain activation of the BCR
downstream factors spleen tyrosine kinase (SYK) and LYN, by
inhibiting AP1-dependent transcription of the phosphatase,
PTPROt.20,66 PTPROt ability to regulate BCR signaling
components have been established using the TCL1/PTPROt
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double-tg mouse,67 which exhibits decreased splenic cells
growth and increased lifespan. For example, the chemokine
CCL3, which is upregulated by BCR signaling, is repressed in
double-tg respect to TCL1-tg mice.
CLL patients exhibit stereotyped BCRs, with unique HCDR3
features and recurrent VH-DH-JH rearrangements, particularly
in the IGHV unmutated cases.68 This observation led to the
hypothesis that a subset of B-cells presenting stereotyped
BCRs is selected by specific antigens such as auto antigens or
microbial antigens and eventually these subsets get trans-
formed by additional genetic abnormalities.1 TCL1-tg BCRs
show HCDR3 characteristics and V(D)J rearrangements
similar to U-CLLs.33 When B-lymphocytes reactive to auto
antigen such as phosphatidylcholine (PtC) are serially
transferred from TCL1-tg into SCID mice, a more aggressive
leukemic clone is selected, showing increased reactivity with
PtC over time. This finding is in agreement with an antigen
selection and drive theory for leukemogenesis.69 An alter-
native hypothesis for BCR-induced CLL pathogenesis is
proposed by Duhren-von Minden et al,70 who found an
autonomous, ligand-independent BCR signaling in CLL
samples from both human patients and TCL1-tg mice. This
represents a new intriguing point of view, which does not
exclude the hypothesis of extrinsic antigen involvement in CLL
pathogenesis. Recently, the intrinsic/extrinsic types of BCR
activation were examined in TCL1mice.71 CLL is supported by
an aberrant auto antigen-driven response and BCR interac-
tions are positively selected by low-affinity auto antigens
during leukemia development. Thus, the two BCR responses
might have independent roles with autonomous BCR activa-
tion being essential for disease initiation and the low-affinity
interaction with external auto antigens providing powerful
co-stimulatory signals.
Altogether these data sustain the importance of therapeutic
approaches based on targeting BCR cascade. The close
resemblance between BCRs from U-CLL patients and
TCL1-tg mice validates the use of this model for preclinical
studies to test the efficacy of inhibitors that block specific
components of BCR pathways.
Inhibitors of BCR Signalosome
Activation of BCR, either by extrinsic or intrinsic stimuli,
transmits to membrane-associated signalosome proteins,
composed of ‘proximal’ kinases such as LYN, SYK, Bruton’s
tyrosine kinase (BTK), BLNK and PI3K. These, in turn,
activate ‘distal’ kinases, primarily ERK and AKT.10 Theoreti-
cally, each of the signalosome components might be a good
candidate for targeted therapy, and increasing number of
promising results have been achieved in this direction, some
of which with the support of mouse models (Figure 1).
Spleen tyrosine kinase. An extensive study on BCR
signaling in TCL1-tg mice was performed by Suljagic et al.
using SYK inhibitors.72 The authors found that SYK and its
direct substrate BLNK are constitutively phosphorylated in
Figure 3 Leukemia-environment interplay within secondary lymphoid organs. A growth-promoting niche named proliferative center is the result of cross talk between tumor
and accessory cells. CLL cells are attracted within LNs through chemokines (i.e., CXCL13 and CCL19/21) secreted by FDC and NLC, that are thought to correspond to leukemia-
associated macrophages (LAM). Here, accessory cells provide a proliferative/survival milieu by secreting cytokines like MIF, BAFF and APRIL. CLL cells in turn, stimulate
cytokine production by accessory cells, induce stromal cell differentiation through LTαβ/LTβR interaction and recruit NLCs and T cells through CCL3/4 secretion. An exhausted
phenotype on T cells is also accomplished by CLL cells, through PD-L1/PD-1 interaction and IL-10 secretion to realize immune escape. Lightning symbols and red letters indicate
new therapeutic targets as discussed in the text
TCL1 mouse model in CLL
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some mice. In any case, BCR engagement led to the
activation of downstream signals such as ERK, AKT, GSK3
and FOXO and this activation was reversed by the SYK
inhibitor R406. Leukemic cells from TCL1-tg mice treated with
R406 prodrug fostamatinib (R788) showed reduced phos-
phorylation at SYK, BLNK and ERK, decreased proliferation
and increased apoptosis. Survival of treated mice was
extended, leading in some cases to the eradication of
malignant clones.72 Fostamatinib is currently tested in phase
II clinical trial for B-cell lymphomas and CLL (NCT00446095).
Bruton’s tyrosine kinase. BTK inhibitor ibrutinib
(PCI-32765) is one of the most recent FDA-approved drugs
for refractory and aggressive 17p deleted form of CLL.73 XID
mice bear a point mutation in Btk gene, which prevents its
kinase activity.74 XID/TCL1 crossed mice have lower tumor
burden in PB and superior survival than TCL1-tg. Similarly to
Btk genetic inactivation, ibrutinib treatment induced an
increased overall survival in treated mice, which was shown
to be dependent from the inhibition of BCR-induced ERK
phosphorylation.74 TCL1-tg mouse also allowed for better
understanding ibrutinib mechanism of action and observa-
tions from patients. For example, during a phase I–II clinical
trial on CLL patients (NCT01105247) it was noted a transient
increase in lymphocytosis, followed by rapid decline during
the days of treatment;75 this effect is probably caused by
ibrutinib-mediated block of chemokine signaling and secre-
tion, that inhibits CLL cells homing in lymphoid organs, and it
was also observed in Eμ-TCL1 mice.76 Nevertheless,
ibrutinib prolongs overall survival in these mice and induces
significant decrease of CLL cells survival and proliferation
demonstrating dual activity.76
LYN kinase and hematopoietic cell-specific LYN
substrate-1 (HS1). HS1 is phosphorylated by SYK and
LYN kinases on BCR engagement and its hyperphosphoryla-
tion correlates with a worst outcome in CLL patients.77
TCL1-tg/Hs1− /− mice show accumulation of leukemic cells in
all lymphoid tissues and shorter survival than TCL1-tg
mice.78 As the genetic inactivation of Hs1 produces the
same effects of hyperphosphorylation, Scielzo et al. conclude
that phosphorylation has an inhibitory effect on HS1.
The therapeutic potential for targeting LYN and HS1 in CLL
has been assessed in TCL1-tg transplantable mouse
model.79 In vitro treatment with the tyrosine kinase inhibitor,
dasatinib, prevents HS1 and ERK phosphorylation, induces
apoptosis and blocks CXCL12 chemotaxis and the interac-
tion with stromal cells. In vivo administration reduces LYN
activity and the percentages of leukemic cells and delays CLL
progression. Thus, dasatinib mechanism of action involves
both cell survival and migration to specific tissues. Further-
more, the study highlighted the importance to analyze LYN/
HS1 axis in CLL patients; in fact, dasatinib variable results in
clinical trials80 may depend on LYN/HS1 activation status.79
Many clinical trials on dasatinib treatment in CLL are currently
ongoing or have been completed (clinicaltrials.gov).
Leukemia-Environment Interplay
Tumor microenvironment contributes to drug resistance and
is crucial for the establishment of CLL proliferative centers,
where malignant cells find optimal conditions to proliferate and
survive. While environmental factors sustain tumor cells,
tumor cells actively strive to establish a microenvironment in
their favor, secreting chemokines that attract supportive
cells and realizing complex strategies to escape immune
surveillance.9 Thus, CLL-microenvironment interplay repre-
sents an interesting therapeutic target (Figure 3). The
importance of microenvironment is also apparent in TCL1-tg
as leukemic cells, obtained from a TCL1-tg donor and selected
by serial transfer in SCID mice, display different response to
BCR signaling based on cell residence:69 these cells actively
proliferate in spleen and LN, but not in BM, peritoneal cavity
and blood, despite their common origin (i.e., the spleen of the
donor) and their clonal nature. Historically, BM has been
considered the most important CLL microenvironment, where
the stromal BM cells (SBMCs) secrete CXCL12 chemokine,
and attract CXCR4-expressing CLL cells. However, increasing
evidence support the relevance of LN. Gene expression
analyses of leukemic cells in CLL patients, revealed a specific
pattern of activation according to the tissue/organ source,
such as PB, BM and LN.81 In particular, genes associated with
signaling of BCR, BAFF/APRIL and some chemokines are
overexpressed in LNs. High expression of phospho-SYK
(BCR signaling) and phospho-p65 (NFkB pathway) are also
found in LN from TCL1-tg mice.
Recently, Heinig et al. provided a clarifying dissection of the
biological and molecular mechanisms underlying CLL cells
homing to the LN.82 By crossing TCL1-tg with Cxcr5− /− mice,
these authors demonstrated this receptor to be indispensable
for recruitment and proliferation of CLL cells into the
germinal center mediated by CXCL13-expressing follicular
dendritic cells (FDCs). In addition, TCL1-tg leukemic cells
themselves are able to induce stromal cell differentiation
through cell-bound lymphotoxin (lymphotoxin-αβ (LTαβ)). The
proposed model is a recruitment of CLL cells by FDCs, via
CXCL13/CXCR5 interaction, into a growth-promoting stromal
niche, which provides BCR stimulation and paracrine
cytokines (mainly BAFF). Reciprocally, leukemic cells induce
stroma remodeling and CXCL13 secretion in a loop controlled
by LTαβ. This mechanism offers at least two therapeutic
targets: the CXCL13-CXCR5 axis and the LTαβ interaction
with its receptor (LTβR), as demonstrated by in vivo treatment
with an LTβR-Ig fusion protein, which abrogates the paracrine
feedback loop between leukemic and stromal cells and retards
leukemia growth.82
Survival cytokines. Accessory cells in the leukemia
microenvironment produce survival factors that inhibit
spontaneous apoptosis. For example, BAFF and APRIL
cytokines are highly expressed by NLCs. Overexpression of
BAFF, by crossing TCL1-tg with BAFF-tg mice, induces faster
development and more aggressive leukemia due to
increased expression of anti-apoptotic proteins. The protec-
tive signal of BAFF is partly mediated by the NFkB pathway,
also activated by TCL1.83 Similar results come from
TCL1/APRIL double-tg.84 APRIL effects on CLL cells mainly
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rely on CD267/TACI TNF-receptor member and this is of
therapeutic relevance as selective targeting of APRIL-TACI
interaction may inhibit leukemic cells survival without affecting
normal B-cells carrying another TNF-receptor member, namely
CD269/BCMA.84
The macrophage migration inhibitory factor (MIF) is a
proinflammatory cytokine acting on B cells, through the
CD74/CD44 receptor complex. MIF loss in TCL1-tg/Mif− /−
mice delays CLL development and reduces leukemic cells
survival.85 In addition, MIF can also act as a chemokine,
recruiting M2 macrophages in leukemic organs, which,
differently to cytotoxic type M1, promote tumor progression
and suppress the immune response. These lymphoma-
associatedmacrophagesmight correspond to NLCs.85 Further
studies revealed a fundamental role for CD44 coreceptor. The
TCL1-tg/Cd44− /− crossed mice86 recapitulate the same
phenotype of the TCL1-tg/Mif− /− mouse model,85 exhibiting a
reduced phosphorylation of major BCR downstream kinases
(SYK, AKTand ERK) and reduced MCL1, no longer inducible
by BCRengagement. AsCD44 genetic deletion ismimicked by
antibody-based targeting,86 MIF/CD44 signal pathway repre-
sents a potential target for therapy, whichmight be investigated
in the TCL1-tg mouse model.
Tumor immune suppression. Besides upregulation of
survival and proliferative pathways by exploiting accessory
cells, CLL cells induce also profound alteration of T-cell
functions to realize tumor immune escape. Indeed, the
rescue of immune surveillance by T cells is one of the
greatest challenges for definitive CLL therapy. Immunosup-
pressive activity of CLL cells in the TCL1-tg mouse model has
been well characterized and proved to be highly similar to
human patients. Regulatory functions for CLL cells are
supported by studies of Di Lillo et al.87 who showed that
molecular mechanism underlying CLL-induced T-cell immu-
nosuppression may be mediated by the cytokine IL-10. The
competence of leukemic cells to express IL-10 either in
human or mouse is normally found in B10 regulatory B cells,
known to negatively regulate the immune response. In fact,
mouse CLL cells suppress T-cell and monocyte/macrophage
activation through IL-10-dependent pathways both in vitro
and in vivo.
Gene expression profiling and protein expression analyses
of CLL T-cells compared with WT or young TCL1-tg mice88
revealed that main changes involve proliferation, differentia-
tion and cytokine/chemokine-response pathways, leading to
functional impairment of antigen recognition, immune
response, T-helper differentiation and cytotoxicity. Of note,
using the transplantation technique a causal relationship
between CLL, B-cells and T-cells changes has been found.88
Further rigorous transplantation experiments definitively
demonstrated that CLL cells rapidly induce T-cell differentia-
tion into memory compartment, probably through a tumor
antigen-driven selection.89 Hence, T cells from human and
TCL1-tg CLLs present a number of dysfunctions such as an
impaired ability to form immunological synapse on conjugation
with antigen-presenting cells, due to defects in cytoskeleton
remodeling and in the recruitment of the T-cell receptor
(TCR).90 The immunomodulatory drug lenalidomide is able
to restore such defect and is extensively investigated in CLL
clinical trials, especially in combination with other drugs
(clinicaltrials.gov). Additional impairments in T-cell differentia-
tion concern: the skewing from a naïve to an antigen-
experienced memory compartment particularly in LNs,89 the
reduction of CD4/CD8 ratios with the loss of central memory
toward CD8+ effector memory pool,91 the exhausted pheno-
type characterized by poor effector function, the reduced
cytokine production, the replicative senescence and finally the
continued expression of inhibitory receptors.92 The latter is
mainly represented by the receptors lymphocyte-activation
gene 3 and programmed cell death 1 (PD-1) with PD-L1/2
ligands, which mediate dephosphorylation of signaling mole-
cules downstream of the TCR. Actually, aberrant PD-1/PD-L1
signaling is involved in all the above mentioned T-cells
dysfunctions.91,92 In fact, normalization of the CD4/CD8 ratio,
activation of T cells with restoring of effector cells cytotoxicity
and immunological synapses formation, resolution of systemic
inflammation and reversal of myeloid skewing are observed in
the TCL1-tg mouse after anti-PD-1 antibody systemic
treatment.93 Although a direct cytotoxic effect of the antibody
on CLL cells was excluded, the treated mice showed
a significant reduction of tumor load in disease-affected
tissues, suggesting that PD-1/PD-L1 blockade is effective in
tumor control restoration through immune effector functions.93
These remarkable results may represent an innovative
strategy to decisively strengthen targeted therapy toward
PI3K/mTOR or BCR signalosome inhibition.
Alternatively, to overcome the defective T-cell antitumor
response, immunotherapy may be addressed to other
cytotoxic effectors like macrophages.94 Treatment with
CpG-containing oligodeoxynucleotides (CpG) synergizes with
anti-CD40 mAb (αCD40) to activate macrophage antitumor
response against human and mouse CLL cells, resulting in
little or no tumor growth. In vitro analysis suggests that killing
ability is partly mediated by nitric oxide synthesis. However,
both human and mouse CLL cells express CD40 and toll-like
receptor 9 (TLR9) and respond to treatment with αCD40 and
CpG themselves, showing increased proliferation and
modest protection from apoptosis. Thus, antitumor effects of
activated macrophages must overcome the proliferative and
anti-apoptotic effects of these stimuli on tumor cells.94
In agreement with this observation, the lack of TIR8 receptor
which normally inhibits the signaling of TLRs, results in earlier
and more aggressive CLL in TCL1-tg/Tir8− /− crossed mice.95
Nevertheless, ligands for TLRs other than TLR9might provide
better and more specific activation of macrophages, resulting
in improvement of CD40-based immunotherapy.
Conclusions
TCL1-tg mouse model has been extensively investigated and
the similarity with human U-CLL is striking. Thus, the TCL1-tg
mouse represents a very useful model for a wide variety of
studies, from basic molecular and cellular mechanisms, to fine
dissection of the pathophysiology of CLL cells, including their
interplay with tumor microenvironment and the preclinical
evaluation of novel therapies. Further, a combination of two or
more inhibitors, targeting pathways that cooperate to the
insurgency, progression and relapse of CLL, is a topic that has
never been tested in this mouse model and would be of
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considerable relevance for CLL therapy. TCL1 is not ubiquitously
expressed being its expression, so far, limited to lymphoid,
myeloid, cutaneous and embryonic cells.15,17,25,26,27 For this
reason, therapies targeting TCL1 such as miRNAs or specific
inhibitors of TCL1 protein in combination with pharmacological
compounds currently used in the treatment of human B-CLL
might represent also an interesting alternative to be tested on
this animal model.
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